Morishita Jintan Co., Ltd. (JP:4524)
:4524
Top Page
Morishita Jintan Co., Ltd.
(4524)
Select Model
Select Model
Rating:62Neutral
Price Target:
¥2,306.00
▲(5.44% Upside)
Action:DowngradedDate:10/10/25
The overall score of 62 reflects a mixed outlook, primarily driven by the company's strong financial stability clashing with weak technical momentum and profitability concerns. The key strength is an exceptionally robust balance sheet with very low debt. However, this is offset by bearish technical indicators suggesting short-term price weakness and an income statement showing compressed margins. The stock's reasonable valuation and attractive dividend yield provide some support.
Positive Factors
Financial Health
A strong balance sheet with low debt enhances financial stability, providing resilience against economic fluctuations and enabling strategic investments.
Negative Factors
Revenue Growth Decline
A decline in revenue growth can signal challenges in market expansion or product demand, potentially impacting long-term financial performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Financial Health
A strong balance sheet with low debt enhances financial stability, providing resilience against economic fluctuations and enabling strategic investments.
Read all positive factors
Morishita Jintan Co., Ltd. (4524) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.37B
Dividend Yield2.55%
Average Volume (3M)1.68K
Price to Earnings (P/E)15.2
Beta (1Y)0.40
Revenue Growth3.23%
EPS Growth42.87%
CountryJP
Employees354
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)35.67
Shares Outstanding4,150,000
10 Day Avg. Volume1,530
30 Day Avg. Volume1,680
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.71
Price to Sales (P/S)0.68
P/FCF Ratio125.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Morishita Jintan Co., Ltd. Business Overview & Revenue Model
Company Description
Morishita Jintan Co., Ltd. produces and distributes pharmaceuticals, quasi drugs, medical devices, and food products in Japan. It operates through Healthcare Business and Capsule Business divisions. The Healthcare Business division manufactures an...
How the Company Makes Money
Morishita Jintan generates revenue through multiple key streams, including the sale of its pharmaceutical products, dietary supplements, and herbal medicines. The company capitalizes on its strong brand reputation and extensive distribution networ...
Morishita Jintan Co., Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
85
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.70B | 12.77B | 12.41B | 11.36B | 9.56B | 9.43B |
| Gross Profit | 5.80B | 5.79B | 6.00B | 5.31B | 4.88B | 4.79B |
| EBITDA | 1.11B | 1.36B | 1.29B | 1.25B | 977.00M | 814.00M |
| Net Income | 465.00M | 547.00M | 697.00M | 491.00M | 283.00M | 206.00M |
Balance Sheet | ||||||
| Total Assets | 17.49B | 17.90B | 17.18B | 16.10B | 14.48B | 14.45B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.94B | 1.09B | 2.41B | 2.14B | 2.70B |
| Total Debt | 1.33B | 1.36B | 270.00M | 469.00M | 749.00M | 1.24B |
| Total Liabilities | 5.51B | 5.74B | 5.04B | 4.71B | 4.02B | 4.17B |
| Stockholders Equity | 11.98B | 12.15B | 12.14B | 11.39B | 10.46B | 10.27B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 69.00M | -455.00M | 715.00M | -159.00M | 284.00M |
| Operating Cash Flow | 0.00 | 669.00M | 196.00M | 1.18B | 543.00M | 871.00M |
| Investing Cash Flow | 0.00 | -701.00M | -1.15B | -474.00M | -463.00M | -502.00M |
| Financing Cash Flow | 0.00 | 880.00M | -362.00M | -433.00M | -645.00M | -141.00M |
Morishita Jintan Co., Ltd. Technical Analysis
Positive
2187.00
Price Trends
2288.84
Positive
2222.75
Positive
2198.78
Positive
Market Momentum
4.21
Positive
55.07
Neutral
32.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4524, the sentiment is Positive. The current price of 2187 is below the 20-day moving average (MA) of 2320.40, below the 50-day MA of 2288.84, and below the 200-day MA of 2198.78, indicating a bullish trend. The MACD of 4.21 indicates Positive momentum. The RSI at 55.07 is Neutral, neither overbought nor oversold. The STOCH value of 32.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4524.
Morishita Jintan Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥440.40B | 15.43 | 7.11% | 2.43% | 3.53% | 38.23% | |
69 Neutral | ¥290.42B | 7.12 | 9.05% | 3.30% | 10.51% | 9.62% | |
62 Neutral | ¥9.37B | 15.24 | ― | 2.55% | 3.23% | 42.87% | |
60 Neutral | ¥20.93B | 5.79 | ― | 3.71% | 7.50% | -281.41% | |
52 Neutral | ¥19.56B | 72.72 | ― | 3.65% | 9.53% | -155.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥11.63B | 7.11 | ― | 1.06% | 5.42% | -62.03% |
* Healthcare Sector Average
JP:4524
Morishita Jintan Co., Ltd.
2,321.00
80.90
3.61%
JP:4530
Hisamitsu Pharmaceutical Co
6,035.00
1,944.01
47.52%
JP:4540
Tsumura & Co
3,796.00
-497.26
-11.58%
JP:2929
Pharma Foods International Co., Ltd.
675.00
-218.71
-24.47%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
353.00
14.12
4.17%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,386.00
-115.26
-4.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.